Euro vs US Dollar

Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

Registrieren

ARQT Arcutis Biotherapeutics Inc

10,26

-0,58 (-5,35%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:52:21

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Masaru Matsuda

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Arcutis Biotherapeutics Charts.

Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Arcutis Biotherapeutics Charts.

News Arcutis Biotherapeutics Inc

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mittwoch 6 November 2024 (6 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Mittwoch 6 November 2024 (6 Tage vor) • Edgar (US Regulatory)

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
Mittwoch 6 November 2024 (6 Tage vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 4 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Montag 4 November 2024 (1 Woche vor) • Edgar (US Regulatory)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Montag 4 November 2024 (1 Woche vor) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Freitag 1 November 2024 (2 Wochen vor) • Edgar (US Regulatory)

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting
Donnerstag 24 Oktober 2024 (3 Wochen vor) • GlobeNewswire Inc.

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
Mittwoch 23 Oktober 2024 (3 Wochen vor) • GlobeNewswire Inc.

Weitere Arcutis Biotherapeutics Inc News-Artikel

Energy Select Sector SPDR

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen